文献速递肿瘤 PET/CT

淋巴瘤患者脂肪肝对肝脏18F-FDG摄取的影响及其对Deauville评分的影响评估

Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-12-26

该研究回顾了227例淋巴瘤患者共358次PET扫描,评估脂肪肝患病率及其对肝脏18F-FDG摄取和Deauville评分的影响。脂肪肝在基线、中期和疗末PET的患病率分别为10.5%、7.6%和11.8%(p=0.62)。脂肪肝组肝脏SULmax在中期和疗末PET显著低于非脂肪肝组,经基于CT密度相关性的方法校正后,所有DS4的脂肪肝患者(中期1例、疗末2例)均转为DS3。

要点

  • 脂肪肝在淋巴瘤患者各时间点PET的患病率为7.6%–11.8%,治疗期间无显著变化(p=0.62)。
  • 脂肪肝组肝脏SULmax在中期(1.66±0.36 vs 2.15±0.27)和疗末(1.67±0.29 vs 2.17±0.30)PET显著低于非脂肪肝组。
  • 校正肝脏SULmax后,中期1例和疗末2例DS4脂肪肝患者均转为DS3。

核心结论

  • 脂肪肝在多数患者中是理论问题而非实际问题,但在适当病例中应被识别并校正,即靶病灶与肝脏背景百分比差异低于30%的DS4患者。

研究设计与样本

  • 回顾性分析1年内227例淋巴瘤患者(122例弥漫大B细胞淋巴瘤、57例霍奇金淋巴瘤、48例滤泡性淋巴瘤)的358次PET扫描,包括基线143次、中期79次和疗末136次。
  • 脂肪肝通过PET/CT非增强CT部分以42 HU为截断值诊断,记录符合EARL标准的肝脏和肿瘤靶病灶SULmax并计算Deauville评分。

主要发现

  • 基线、中期和疗末PET脂肪肝患病率分别为15/143(10.5%)、6/79(7.6%)和16/136(11.8%)(p=0.62)。
  • 27例脂肪肝患者中10例(37.0%)在所有检查中均显示脂肪肝,6例(22.2%)在治疗过程中脂肪肝消失,仅1例在治疗过程中出现脂肪肝。
  • 脂肪肝组肝脏SULmax在中期PET为1.66±0.36 vs 非脂肪肝组2.15±0.27,疗末PET为1.67±0.29 vs 2.17±0.30,均显著低于非脂肪肝组。
  • CT密度是与肝脏SULmax相关的独立因素,而BMI、血糖水平和化疗方案类型不是。
  • 使用基于该相关性的方法校正肝脏SULmax后,中期DS4脂肪肝患者1例和疗末DS4脂肪肝患者2例均转为DS3。

关键数值与推荐

  • 脂肪肝诊断截断值为42 HU。
  • 脂肪肝组肝脏SULmax中期1.66±0.36 vs 非脂肪肝组2.15±0.27;疗末1.67±0.29 vs 2.17±0.30。
  • 校正肝脏SULmax后,中期1例和疗末2例DS4脂肪肝患者转为DS3。

临床怎么用

  • 作者认为脂肪肝在多数患者中是理论问题而非实际问题,但在适当病例中应被识别并校正,即靶病灶与肝脏背景百分比差异低于30%的DS4患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Our aim was (1) to evaluate the prevalence of steatosis in lymphoma patients and its evolution during treatment; (2) to evaluate the impact of hepatic steatosis on 18F-FDG liver uptake; and (3) to study how hepatic steatosis affects the Deauville score (DS) for discriminating between responders and non-responders. METHODS: Over a 1-year period, 358 PET scans from 227 patients [122 diffuse large B cell lymphoma (DLBCL), 57 Hodgkin lymphoma (HL) and 48 Follicular lymphoma (FL)] referred for baseline (n = 143), interim (n = 79) and end-of-treatment (EoT, n = 136) PET scans were reviewed. Steatosis was diagnosed on the unenhanced CT part of PET/CT examinations using a cut-off value of 42 Hounsfield units (HU). EARL-compliant SULmax were recorded on the liver and the tumour target lesion. DS were then computed. RESULTS: Prevalence of steatosis at baseline, interim and EoT PET was 15/143 (10.5%), 6/79 (7.6%) and 16/136 (11.8%), respectively (p = 0.62).Ten out of 27 steatotic patients (37.0%) displayed a steatotic liver on all examinations. Six patients (22.2%) had a disappearance of hepatic steatosis during their time-course of treatment. Only one patient developed steatosis during his course of treatment. Liver SULmax values were significantly lower in the steatosis versus non-steatotic groups of patients for interim (1.66 ± 0.36 versus 2.15 ± 0.27) and EoT (1.67 ± 0.29 versus 2.17 ± 0.30) PET. CT density was found to be an independent factor that correlated with liver SULmax, while BMI, blood glucose level and the type of chemotherapy regimen were not. Using a method based on this correlation to correct liver SULmax, all DS4 steatotic patients on interim (n = 1) and EoT (n = 2) PET moved to DS3. CONCLUSIONS: Steatosis is actually a theoretical but not practical issue in most patients but should be recognised and corrected in appropriate cases, namely, for those patients scored DS4 with a percentage difference between the target lesion and the liver background lower than 30%.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Salomon T, Nganoa C, Gac AC, et al. Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. Eur J Nucl Med Mol Imaging. 2017. PMID: 29279943. doi:10.1007/s00259-017-3914-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。